伴隨式診斷的全球市場:市場規模,佔有率,趨勢分析,機會,預測 - 各各產品、服務,各技術,各適應症,各終端用戶,各地區(2019年~2029年)
市場調查報告書
商品編碼
1227623

伴隨式診斷的全球市場:市場規模,佔有率,趨勢分析,機會,預測 - 各各產品、服務,各技術,各適應症,各終端用戶,各地區(2019年~2029年)

Companion Diagnostics Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Product & Service ; By Technology ; By Indication ; By End User ; By Region

出版日期: | 出版商: Blueweave Consulting | 英文 400 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

全球伴隨式診斷的市場規模,2022年達到61億2,000萬美金,預計2029年達135億7,000萬美元,在2023年~2029年的預測期間內以12.15%的年複合成長率成長。

全球市場,由於醫藥品和診斷技術的共同開發,醫藥品副作用的劇增,個體化治療的需求高漲,呈現蓬勃發展。

本報告提供全球伴隨式診斷市場相關調查,市場洞察,市場概要,各地區的市場分析,競爭情形,企業簡介等相關資訊。

目錄

第1章 調查架構

第2章 摘要整理

第3章 全球伴隨式診斷市場洞察

  • 產業價值鏈分析
  • DROC分析
    • 促進因素
      • 醫藥品副作用增加
      • 醫藥品和診斷技術的共同開發
    • 阻礙因素
      • 醫藥品開發及相關的臨床試驗的高成本
    • 機會
      • 次世代定序的需求高漲
    • 課題
      • 許多國家的償付課題
  • 技術的進步/最近的開發
  • 法律規範
  • 波特的五力分析
    • 供給企業談判力
    • 買方議價能力
    • 新加入廠商的威脅
    • 替代品的威脅
    • 競爭激烈度

第4章 全球伴隨式診斷的市場概要

  • 市場規模、預測,2019年~2029年
    • 各金額(10億美元)
  • 市場佔有率、預測
    • 各產品、服務
      • 化驗,套件、試劑
      • 軟體、服務
    • 各技術
      • 聚合酵素鏈鎖反應
      • 次世代定序
      • In situ雜合反應
      • 免疫組織化學
      • 其他
    • 各適應症
      • 癌症
      • 神經疾病
      • 心血管疾病
      • 感染疾病
      • 其他
    • 各終端用戶
      • 醫藥品、生物醫藥品
      • 參考實驗室
      • 受託研究機構
      • 其他
    • 各地區
      • 北美
      • 歐洲
      • 亞太地區
      • 南美
      • 中東、非洲

第5章 北美的伴隨式診斷市場

  • 市場規模、預測,2019年~2029年
    • 各金額(10億美元)
  • 市場佔有率、預測
    • 各產品、服務
    • 各技術
    • 各適應症
    • 各終端用戶
    • 各國
      • 美國
      • 加拿大

第6章 歐洲的伴隨式診斷市場

  • 市場規模、預測,2019年~2029年
    • 各金額(10億美元)
  • 市場佔有率、預測
    • 各產品、服務
    • 各技術
    • 各適應症
    • 各終端用戶
    • 各國
      • 德國
      • 英國
      • 義大利
      • 法國
      • 西班牙
      • 荷蘭
      • 其他的歐洲

第7章 亞太地區的伴隨式診斷市場

  • 市場規模、預測,2019年~2029年
    • 各金額(10億美元)
  • 市場佔有率、預測
    • 各產品、服務
    • 各技術
    • 各適應症
    • 各終端用戶
    • 各國
      • 中國
      • 印度
      • 日本
      • 韓國
      • 澳洲、紐西蘭
      • 印尼
      • 馬來西亞
      • 新加坡
      • 菲律賓
      • 越南
      • 其他的亞太地區

第8章 南美的伴隨式診斷市場

  • 市場規模、預測,2019年~2029年
    • 各金額(10億美元)
  • 市場佔有率、預測
    • 各產品、服務
    • 各技術
    • 各適應症
    • 各終端用戶
    • 各國
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘魯
      • 其他的南美

第9章 中東、非洲的伴隨式診斷市場

  • 市場規模、預測,2019年~2029年
    • 各金額(10億美元)
  • 市場佔有率、預測
    • 各產品、服務
    • 各技術
    • 各適應症
    • 各終端用戶
    • 各國
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 科威特
      • 南非
      • 奈及利亞
      • 阿爾及利亞
      • 其他的中東、非洲

第10章 競爭情形

  • 主要企業產品清單
  • 全球伴隨式診斷企業的市場佔有率分析,2022年
  • 競爭基準:各運用參數
  • 主要的策略性開發(合併,收購,夥伴關係等)

第11章 全球伴隨式診斷市場上COVID-19的影響

第12章 企業簡介(企業概要,財務矩陣,競爭情形,主要的人力資源,主要的競爭企業,聯絡處,策略性展望,SWOT分析)

  • Abbott Laboratories Inc.
  • Agilent Technologies Inc.
  • F. Hoffmann-La Roche Ltd
  • Biomerieux SA
  • Qiagen NV
  • Siemens Healthcare
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation(Beckman Coulter Inc.)
  • Almac Group
  • Illumina Inc.
  • Myriad Genetics Inc.
  • Sysmex Corporation
  • Abnova Corporation
  • Guardant Health Inc
  • 其他的主要企業

第13章 主要策略性推薦事項

第14章 調查手法

簡介目錄
Product Code: BWC20380

Global Companion Diagnostics Market Size More Than Doubles to Touch USD 13.6 billion by 2029.

Global companion diagnostics market is flourishing because rising co-development of drug and diagnostic technology, surging incidences of adverse drug reactions, and increasing need for personalized treatment.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated global companion diagnostics market size at USD 6.12 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects global companion diagnostics market size to grow at a significant CAGR of 12.15% reaching a value of USD 13.57 billion by 2029. Major growth factors of global companion diagnostics market include increasing requirement for personalized treatment, broad application areas of companion diagnostics, surging demand for focused therapy, growing cancer occurrences, and development of new biomarkers for various illnesses. Personalized medicine is becoming increasingly popular as the field of genetics and genetic engineering expands fast. It is now possible to provide the correct medicine to the right individual at the right time based on a person's genetic features. As part of a patient-centric drug development approach, many pharmaceutical and biopharmaceutical companies are developing targeted medication therapies. Numerous third-party companion diagnostic services provide similar services to enterprises that face a greater financial strain. As a result, the issue of high startup expenses has been effectively handled. These reasons are projected to drive the companion diagnostics market during the forecast period. However, increasing expense of drug development and associated clinical trials during the period in analysis.

Global Companion Diagnostics Market - Overview:

A companion diagnostics device is a medical gadget that is used in conjunction with therapeutic medications to assess the effect and applicability of drugs on a specific human body. Companion diagnostics are developed in tandem with medications to select or exclude patient groups based on the features to which they respond to therapy. This device assists the healthcare provider in determining whether a specific treatment is beneficial to the patient. In 2020, Roche gained FDA approval for Cobas EGFR Mutation Test v2 companion diagnostic for EGFR tyrosine kinase inhibitor for lung cancer treatment. Companion Diagnostic (CDx) is a clinical test created in collaboration with a therapeutic medicine to identify responders and non-responders to that therapy. It is done to determine which patient groups may and cannot be treated with the relevant medicine. CDx assists practitioners in determining the benefits, side effects, and hazards connected with therapeutic drug intake, guaranteeing patient safety. Growing patient preferences for customized therapy, expanding applications of personalized medications, increased prevalence of chronic diseases, and rising occurrences of allergies in patients as a result of medication adverse effects all contribute to the development of customized CDx, propelling the global Companion Diagnostics Market forward. Furthermore, CDx tests' features, such as cost-effectiveness, high sensitivity, and rapid and precise results in short timeframes, aid in the expansion of the companion diagnostics market.

Impact of COVID-19 on Global Companion Diagnostics Market

COVID-19 had a detrimental impact on the companion diagnostics market. In addition, prominent market participants witnessed a considerable drop in income owing to a fall in testing volume and other variables. In terms of sales, the market grew by 15.1% in 2020, compared to 19.8% in 2019. Revenue generated by the major players decreased significantly in 2020. However, the lifting of lockdown restrictions, stay-at-home orders in many nations, the introduction of novel diagnostic tests, and the re-establishment of the supply chain network were major contributors in the recovery of testing in 2021. As a result, the restart of cancer diagnostics testing, and the introduction of novel diagnostic tests boosted demand in 2021.

Global Companion Diagnostics Market - By Indication:

Based on indication, global companion diagnostics market is divided into Cancer, Neurological Disorders, Cardiovascular Diseases, and Infectious Diseases. In 2022, the cancer segment held the highest market share. Increased cancer prevalence, an increase in the number of cancer R&D activities, an increase in the number of unmet needs for cancer treatment, an increase in the number of FDA-approved companion diagnostics, and increased patient awareness about personalized medicine are some of the key factors driving the growth of the oncology segment. The cancer segment includes lung cancer, breast cancer, blood cancer, and colorectal cancer. Amongst them, lung cancer holds the highest market share. Companion diagnostic tests (CDXs) are regarded mandatory in the decision-making process for lung cancer treatment with targeted treatments. Individuals with lung cancer who undergo companion diagnostics as part of their initial treatment have a higher chance of surviving than those who do not. Globally, the increasing incidence rate of non-small cell lung cancer (NSCLC), combined with an increase in the development of oncology companion diagnostic tests for the disease, is likely to drive sector growth.

Competitive Landscape:

Major players operating in global companion diagnostics market include: Abbott Laboratories Inc., Agilent Technologies Inc., F. Hoffmann-La Roche Ltd, Biomerieux SA, Qiagen NV, Siemens Healthcare, Thermo Fisher Scientific Inc., Danaher Corporation (Beckman Coulter Inc.), Almac Group, Illumina Inc., Myriad Genetics Inc., Sysmex Corporation, Abnova Corporation, and Guardant Health Inc. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Companion Diagnostics Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Companion Diagnostics Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Companion Diagnostics Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Increasing Cases of Adverse Drug Reactions
      • 3.2.1.2. Co-development of Drug and Diagnostic Technology
    • 3.2.2. Restraints
      • 3.2.2.1. High Cost of Drug Development and Associated Clinical Trials
    • 3.2.3. Opportunities
      • 3.2.3.1. Rising Demand for Next Generation Sequencing
    • 3.2.4. Challenges
      • 3.2.4.1. Reimbursement Issues Among Many Countries
  • 3.3. Technology Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Companion Diagnostics Market Overview

  • 4.1. Market Size & Forecast, 2019-2029
    • 4.1.1. By Value (USD Billion)
  • 4.2. Market Share & Forecast
    • 4.2.1. By Product & Service
      • 4.2.1.1. Assays, Kits & Reagents
      • 4.2.1.2. Software & Services
    • 4.2.2. By Technology
      • 4.2.2.1. Polymerase Chain Reaction
      • 4.2.2.2. Next-generation Sequencing
      • 4.2.2.3. In Situ Hybridization
      • 4.2.2.4. Immunohistochemistry
      • 4.2.2.5. Others
    • 4.2.3. By Indication
      • 4.2.3.1. Cancer
      • 4.2.3.1.1. Lung Cancer
      • 4.2.3.1.2. Breast Cancer
      • 4.2.3.1.3. Blood Cancer
      • 4.2.3.1.4. Colorectal Cancer
      • 4.2.3.1.5. Others
      • 4.2.3.2. Neurological Disorders
      • 4.2.3.3. Cardiovascular Diseases
      • 4.2.3.4. Infectious Diseases
      • 4.2.3.5. Others
    • 4.2.4. By End User
      • 4.2.4.1. Pharmaceutical & Biopharmaceutical
      • 4.2.4.2. Reference Laboratories
      • 4.2.4.3. Contract Research Organizations
      • 4.2.4.4. Others
    • 4.2.5. By Region
      • 4.2.5.1. North America
      • 4.2.5.2. Europe
      • 4.2.5.3. Asia Pacific (APAC)
      • 4.2.5.4. Latin America (LATAM)
      • 4.2.5.5. Middle East and Africa (MEA)

5. North America Companion Diagnostics Market

  • 5.1. Market Size & Forecast, 2019-2029
    • 5.1.1. By Value (USD Billion)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product & Service
    • 5.2.2. By Technology
    • 5.2.3. By Indication
    • 5.2.4. By End User
    • 5.2.5. By Country
      • 5.2.5.1. US
      • 5.2.5.1.1. By Product & Service
      • 5.2.5.1.2. By Technology
      • 5.2.5.1.3. By Indication
      • 5.2.5.1.4. By End User
      • 5.2.5.2. Canada
      • 5.2.5.2.1. By Product & Service
      • 5.2.5.2.2. By Technology
      • 5.2.5.2.3. By Indication
      • 5.2.5.2.4. By End User

6. Europe Companion Diagnostics Market

  • 6.1. Market Size & Forecast, 2019-2029
    • 6.1.1. By Value (USD Billion)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product & Service
    • 6.2.2. By Technology
    • 6.2.3. By Indication
    • 6.2.4. By End User
    • 6.2.5. By Country
      • 6.2.5.1. Germany
      • 6.2.5.1.1. By Product & Service
      • 6.2.5.1.2. By Technology
      • 6.2.5.1.3. By Indication
      • 6.2.5.1.4. By End User
      • 6.2.5.2. UK
      • 6.2.5.2.1. By Product & Service
      • 6.2.5.2.2. By Technology
      • 6.2.5.2.3. By Indication
      • 6.2.5.2.4. By End User
      • 6.2.5.3. Italy
      • 6.2.5.3.1. By Product & Service
      • 6.2.5.3.2. By Technology
      • 6.2.5.3.3. By Indication
      • 6.2.5.3.4. By End User
      • 6.2.5.4. France
      • 6.2.5.4.1. By Product & Service
      • 6.2.5.4.2. By Technology
      • 6.2.5.4.3. By Indication
      • 6.2.5.4.4. By End User
      • 6.2.5.5. Spain
      • 6.2.5.5.1. By Product & Service
      • 6.2.5.5.2. By Technology
      • 6.2.5.5.3. By Indication
      • 6.2.5.5.4. By End User
      • 6.2.5.6. The Netherlands
      • 6.2.5.6.1. By Product & Service
      • 6.2.5.6.2. By Technology
      • 6.2.5.6.3. By Indication
      • 6.2.5.6.4. By End User
      • 6.2.5.7. Rest of Europe
      • 6.2.5.7.1. By Product & Service
      • 6.2.5.7.2. By Technology
      • 6.2.5.7.3. By Indication
      • 6.2.5.7.4. By End User

7. Asia-Pacific Companion Diagnostics Market

  • 7.1. Market Size & Forecast, 2019-2029
    • 7.1.1. By Value (USD Billion)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product & Service
    • 7.2.2. By Technology
    • 7.2.3. By Indication
    • 7.2.4. By End User
    • 7.2.5. By Country
      • 7.2.5.1. China
      • 7.2.5.1.1. By Product & Service
      • 7.2.5.1.2. By Technology
      • 7.2.5.1.3. By Indication
      • 7.2.5.1.4. By End User
      • 7.2.5.2. India
      • 7.2.5.2.1. By Product & Service
      • 7.2.5.2.2. By Technology
      • 7.2.5.2.3. By Indication
      • 7.2.5.2.4. By End User
      • 7.2.5.3. Japan
      • 7.2.5.3.1. By Product & Service
      • 7.2.5.3.2. By Technology
      • 7.2.5.3.3. By Indication
      • 7.2.5.3.4. By End User
      • 7.2.5.4. South Korea
      • 7.2.5.4.1. By Product & Service
      • 7.2.5.4.2. By Technology
      • 7.2.5.4.3. By Indication
      • 7.2.5.4.4. By End User
      • 7.2.5.5. Australia & New Zealand
      • 7.2.5.5.1. By Product & Service
      • 7.2.5.5.2. By Technology
      • 7.2.5.5.3. By Indication
      • 7.2.5.5.4. By End User
      • 7.2.5.6. Indonesia
      • 7.2.5.6.1. By Product & Service
      • 7.2.5.6.2. By Technology
      • 7.2.5.6.3. By Indication
      • 7.2.5.6.4. By End User
      • 7.2.5.7. Malaysia
      • 7.2.5.7.1. By Product & Service
      • 7.2.5.7.2. By Technology
      • 7.2.5.7.3. By Indication
      • 7.2.5.7.4. By End User
      • 7.2.5.8. Singapore
      • 7.2.5.8.1. By Product & Service
      • 7.2.5.8.2. By Technology
      • 7.2.5.8.3. By Indication
      • 7.2.5.8.4. By End User
      • 7.2.5.9. Philippines
      • 7.2.5.9.1. By Product & Service
      • 7.2.5.9.2. By Technology
      • 7.2.5.9.3. By Indication
      • 7.2.5.9.4. By End User
      • 7.2.5.10. Vietnam
      • 7.2.5.10.1. By Product & Service
      • 7.2.5.10.2. By Technology
      • 7.2.5.10.3. By Indication
      • 7.2.5.10.4. By End User
      • 7.2.5.11. Rest of APAC
      • 7.2.5.11.1. By Product & Service
      • 7.2.5.11.2. By Technology
      • 7.2.5.11.3. By Indication
      • 7.2.5.11.4. By End User

8. Latin America Companion Diagnostics Market

  • 8.1. Market Size & Forecast, 2019-2029
    • 8.1.1. By Value (USD Billion)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product & Service
    • 8.2.2. By Technology
    • 8.2.3. By Indication
    • 8.2.4. By End User
    • 8.2.5. By Country
      • 8.2.5.1. Brazil
      • 8.2.5.1.1. By Product & Service
      • 8.2.5.1.2. By Technology
      • 8.2.5.1.3. By Indication
      • 8.2.5.1.4. By End User
      • 8.2.5.2. Mexico
      • 8.2.5.2.1. By Product & Service
      • 8.2.5.2.2. By Technology
      • 8.2.5.2.3. By Indication
      • 8.2.5.2.4. By End User
      • 8.2.5.3. Argentina
      • 8.2.5.3.1. By Product & Service
      • 8.2.5.3.2. By Technology
      • 8.2.5.3.3. By Indication
      • 8.2.5.3.4. By End User
      • 8.2.5.4. Peru
      • 8.2.5.4.1. By Product & Service
      • 8.2.5.4.2. By Technology
      • 8.2.5.4.3. By Indication
      • 8.2.5.4.4. By End User
      • 8.2.5.5. Rest of LATAM
      • 8.2.5.5.1. By Product & Service
      • 8.2.5.5.2. By Technology
      • 8.2.5.5.3. By Indication
      • 8.2.5.5.4. By End User

9. Middle East & Africa Companion Diagnostics Market

  • 9.1. Market Size & Forecast, 2019-2029
    • 9.1.1. By Value (USD Billion)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product & Service
    • 9.2.2. By Technology
    • 9.2.3. By Indication
    • 9.2.4. By End User
    • 9.2.5. By Country
      • 9.2.5.1. Saudi Arabia
      • 9.2.5.1.1. By Product & Service
      • 9.2.5.1.2. By Technology
      • 9.2.5.1.3. By Indication
      • 9.2.5.1.4. By End User
      • 9.2.5.2. UAE
      • 9.2.5.2.1. By Product & Service
      • 9.2.5.2.2. By Technology
      • 9.2.5.2.3. By Indication
      • 9.2.5.2.4. By End User
      • 9.2.5.3. Qatar
      • 9.2.5.3.1. By Product & Service
      • 9.2.5.3.2. By Technology
      • 9.2.5.3.3. By Indication
      • 9.2.5.3.4. By End User
      • 9.2.5.4. Kuwait
      • 9.2.5.4.1. By Product & Service
      • 9.2.5.4.2. By Technology
      • 9.2.5.4.3. By Indication
      • 9.2.5.4.4. By End User
      • 9.2.5.5. South Africa
      • 9.2.5.5.1. By Product & Service
      • 9.2.5.5.2. By Technology
      • 9.2.5.5.3. By Indication
      • 9.2.5.5.4. By End User
      • 9.2.5.6. Nigeria
      • 9.2.5.6.1. By Product & Service
      • 9.2.5.6.2. By Technology
      • 9.2.5.6.3. By Indication
      • 9.2.5.6.4. By End User
      • 9.2.5.7. Algeria
      • 9.2.5.7.1. By Product & Service
      • 9.2.5.7.2. By Technology
      • 9.2.5.7.3. By Indication
      • 9.2.5.7.4. By End User
      • 9.2.5.8. Rest of MEA
      • 9.2.5.8.1. By Product & Service
      • 9.2.5.8.2. By Technology
      • 9.2.5.8.3. By Indication
      • 9.2.5.8.4. By End User

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Companion Diagnostics Company Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Companion Diagnostics Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

  • 12.1. Abbott Laboratories Inc.
  • 12.2. Agilent Technologies Inc.
  • 12.3. F. Hoffmann-La Roche Ltd
  • 12.4. Biomerieux SA
  • 12.5. Qiagen NV
  • 12.6. Siemens Healthcare
  • 12.7. Thermo Fisher Scientific Inc.
  • 12.8. Danaher Corporation (Beckman Coulter Inc.)
  • 12.9. Almac Group
  • 12.10. Illumina Inc.
  • 12.11. Myriad Genetics Inc.
  • 12.12. Sysmex Corporation
  • 12.13. Abnova Corporation
  • 12.14. Guardant Health Inc
  • 12.15. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumptions & Limitations